We are live on ! Find out more
WX

WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX

Delisted

WX was delisted on the 10th of December, 2015.

164 hedge funds and large institutions have $2.28B invested in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in 2013 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 64 increasing their positions, 48 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

320% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 10

83% more call options, than puts

Call options by funds: $1.87M | Put options by funds: $1.02M

40% more capital invested

Capital invested by funds: $1.63B → $2.28B (+$650M)

33% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 48

24% more funds holding

Funds holding: 132164 (+32)

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

Holders
164
Holders Change
+32
Holders Change %
+24.24%
% of All Funds
4.76%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.2%
New
42
Increased
64
Reduced
48
Closed
10
Calls
$1.87M
Puts
$1.02M
Net Calls
+$848K
Net Calls Change
+$439K
Name Holding Trade Value Shares
Change
Change in
Stake
UBS AM
26
UBS AM
Illinois
$23.9M +$18M +569,959 +1,057%
PPA
27
Parametric Portfolio Associates
Washington
$22.9M -$1.86M -58,987 -9%
RG
28
Renaissance Group
Kentucky
$20.7M -$2.79M -88,350 -14%
QBFM
29
QS Batterymarch Financial Management
New York
$18.3M -$3.53M -111,767 -19%
RFC
30
Russell Frank Company
Washington
$14.1M +$5.34M +169,204 +74%
BIM
31
Bogle Investment Management
Massachusetts
$13.8M +$2.24M +70,844 +24%
LBA
32
Letko, Brosseau & Associates
Quebec, Canada
$13.7M
MAA
33
Managed Account Advisors
New Jersey
$11.9M +$6.39M +202,526 +188%
DP
34
Delta Partners
Massachusetts
$11.9M
CS
35
Credit Suisse
Switzerland
$11.4M -$2.08M -65,782 -18%
OAM
36
Origin Asset Management
United Kingdom
$10.9M +$7.36M +233,100 +453%
SR
37
Sloane Robinson
United Kingdom
$9.51M -$1.75M -55,400 -18%
PAM
38
Panagora Asset Management
Massachusetts
$9.37M +$1.73M +54,846 +29%
JAM
39
Jupiter Asset Management
United Kingdom
$9M -$931K -29,500 -11%
GPGA
40
Grandeur Peak Global Advisors
Utah
$8.84M +$637K +20,185 +10%
BTS
41
BB&T Securities
Virginia
$8.65M +$712K +22,539 New
MCM
42
McKinley Capital Management
Alaska
$8.56M -$1.33M -42,067 -16%
PC
43
Pier Capital
Connecticut
$8.38M -$1.82M -57,800 -21%
WHG
44
Westwood Holdings Group
Texas
$8.22M +$2.56M +80,958 +61%
GC
45
Gratry & Company
Ohio
$7.9M +$6.5M +205,800 New
IAM
46
Integre Asset Management
New York
$7.68M -$208K -6,584 -3%
CGI
47
CI Global Investments
California
$7.68M +$6.31M +200,000 New
Boston Partners
48
Boston Partners
Massachusetts
$7.39M
State Street
49
State Street
Massachusetts
$7.02M -$329K -10,414 -5%
BA
50
BlackRock Advisors
Delaware
$6.94M -$2.8M -88,622 -33%

WX Hedge Fund Activity: Q4 2013 in Review

164 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) for Q4 2013, worth a combined $2.28B — up 40% from $1.63B a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new WX positions and 10 closed out — a net gain of 32 holders — while 64 added to existing stakes and 48 trimmed.

The largest buyer was Mirae Asset Global Investments, adding an estimated $26.5M. The largest seller was Fidelity International, cutting an estimated $38.1M.

  • 164 institutional investors held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) as of Q4 2013, up from 132 in Q3 2013.
  • Funds reported $2.28B of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS stock for Q4 2013, up 40% quarter-over-quarter.
  • 42 funds opened new WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS positions in Q4 2013 and 10 closed out, a net change of +32 holders.
  • The largest WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS buyer in Q4 2013 was Mirae Asset Global Investments, an estimated $26.5M added.
  • The largest WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS seller in Q4 2013 was Fidelity International, an estimated $38.1M sold.

Based on aggregated 13F filings for Q4 2013.